Could RO7851624, newly into clinical trials, be RG6735?
ApexOnco Front Page
Recent articles
The company sidelines CDK2 and pan-KRAS blockers, among other projects.
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
Pfizer reveals the discontinuation of PF-08046044.
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
The company will try to get the Komzifti QTc prolongation warning removed.
It’s less about being fast, more about producing a better product.
